Skip to main content

Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.

Publication ,  Journal Article
Pollack, CV; Bernstein, R; Dubiel, R; Reilly, P; Gruenenfelder, F; Huisman, MV; Kam, C-W; Kleine, E; Levy, JH; Sellke, FW; Steiner, T ...
Published in: J Med Econ
May 2017

AIMS: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate. MATERIALS AND METHODS: RE-VERSE AD™ (NCT02104947), a prospective, multi-center open-label study, is evaluating idarucizumab for dabigatran reversal in patients with serious bleeding (Group A) or undergoing emergency surgery/procedures (Group B). HCRU outcome measures evaluated in the first 90 patients enrolled were use of blood products and pro-hemostatic agents, length of stay (LOS) in hospital, and LOS in intensive care unit (ICU). RESULTS: Blood products or pro-hemostatic agents were given to 63% (32/51) of patients in Group A and 23% (9/39) of patients in Group B on the day of/day after surgery. An overnight hospital stay was reported for 82% (42/51) of patients in Group A with median LOS = 7 (range = 1-71) bed-days. For Group B, 92% (36/39) had an overnight hospital stay with a median LOS = 9 (range = 1-92) bed-days. In Group A, 17 patients were admitted to the ICU for at least 1 day with median LOS = 4 (range = 1-44) days; in Group B the number was 15 with median LOS = 2 (range = 1-92) days. LIMITATIONS: The lack of a control group and the small patient numbers limit the strength of the conclusions. CONCLUSIONS: The use of idarucizumab may simplify emergency management of dabigatran-treated patients with life-threatening bleeds and reduce perioperative complications in patients undergoing emergency surgery.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Med Econ

DOI

EISSN

1941-837X

Publication Date

May 2017

Volume

20

Issue

5

Start / End Page

435 / 442

Location

England

Related Subject Headings

  • Time Factors
  • Prospective Studies
  • Models, Econometric
  • Middle Aged
  • Male
  • Length of Stay
  • Intensive Care Units
  • Humans
  • Hemostatics
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pollack, C. V., Bernstein, R., Dubiel, R., Reilly, P., Gruenenfelder, F., Huisman, M. V., … Weitz, J. I. (2017). Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ, 20(5), 435–442. https://doi.org/10.1080/13696998.2016.1273229
Pollack, Charles V., Richard Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak-Wah Kam, et al. “Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.J Med Econ 20, no. 5 (May 2017): 435–42. https://doi.org/10.1080/13696998.2016.1273229.
Pollack CV, Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, Kam C-W, Kleine E, Levy JH, Sellke FW, Steiner T, Ustyugova A, Weitz JI. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ. 2017 May;20(5):435–442.

Published In

J Med Econ

DOI

EISSN

1941-837X

Publication Date

May 2017

Volume

20

Issue

5

Start / End Page

435 / 442

Location

England

Related Subject Headings

  • Time Factors
  • Prospective Studies
  • Models, Econometric
  • Middle Aged
  • Male
  • Length of Stay
  • Intensive Care Units
  • Humans
  • Hemostatics
  • Hemorrhage